Their Number Said “Optimal.” They Were in a Hospital Bed.
UCLA counted 136,905 heart-disease hospitalizations. Almost half came in with the cholesterol number the guidelines called optimal. The panel that moved the line, what its members disclosed, and the two places your checkup never looks.
Los Angeles, 2009. 136,905 hospital stays.
There is a reason your doctor checks one number every year and treats it as the story of your heart.
In 2009 a team at UCLA, with cardiologist Gregg Fonarow as senior author, went through a national hospital registry called Get With The Guidelines. They pulled every stay for coronary heart disease at 541 hospitals between 2000 and 2006 where the patient’s cholesterol had been tested in the first 24 hours.
That came to 136,905 hospitalizations.
They asked a simple question. When people land in the hospital with heart disease, what does their cholesterol look like?
Almost half came in with LDL, the “bad” cholesterol, under 100. That was the number the federal guidelines of the time called optimal. Only 1.4% had the full profile the guidelines call ideal. (Sachdeva et al., American Heart Journal, 2009)
Their number said optimal. They were in a hospital bed.
None of this is hidden. It was published in one of cardiology’s own journals. What the system did around it is the part nobody tells you.
The number you were sold
For most of your adult life, cholesterol has been the scoreboard for your heart. It is on every checkup. It is the number your doctor writes down, the number you remember, the number a pill was built to bring down.
In 2001 the federal government’s cholesterol panel, the National Cholesterol Education Program’s Adult Treatment Panel III, wrote it into a table: LDL under 100 was “optimal.” (NHLBI, ATP III, 2001)
If you were under that line, you were told you were doing well. Almost half of those 136,905 hospital stays were under that line.
By the time UCLA published, the line had already been moved once. Who moved it matters.
Who moved the line
On July 13, 2004, a nine-member working group of that same federal program published an update in the journal Circulation. For patients at the highest risk, it made an LDL of 70 “a therapeutic option,” a goal that extended, in its own words, even to patients who were already under 100. (Grundy et al., Circulation, 2004)
The National Heart, Lung, and Blood Institute published the group’s financial disclosures on its own website.
Eight of the nine had financial ties to companies that make cholesterol drugs:
- Eight to Merck.
- Seven to Pfizer.
The chair, Scott Grundy, listed honoraria from Merck, Pfizer, Sankyo, Bayer, Merck/Schering-Plough, Kos, Abbott, Bristol-Myers Squibb and AstraZeneca, and research grants from Merck, Abbott and GlaxoSmithKline. The one member with nothing to disclose was the government’s own staff scientist. (NHLBI, ATP III Update 2004: Financial Disclosure)
Five years later, UCLA counted the hospital beds and found almost half had come in under the old “optimal” line. Their conclusion, in their own words: the findings “may provide further support for recent guideline revisions with even lower LDL goals.”
Even lower.
- In 2013 the American College of Cardiology and the American Heart Association rewrote the rules.
- Researchers at Duke ran the new rules against a national health survey and published the count in the New England Journal of Medicine.
- The number of American adults aged 40 to 75 taking or eligible for a statin went from 43.2 million to 56.0 million.
That is 12.8 million more, and 10.4 million of them had no cardiovascular disease. (Pencina et al., NEJM, 2014)
Nobody had to break a rule for any of this to happen. Every line above is printed in the record, by the people who did it.
Whether you take a statin stays between you and your doctor, and this article is about who moved the line your doctor works inside.
The record, line by line:
❌ 136,905 heart-disease hospitalizations reviewed at 541 hospitals (UCLA)
❌ Almost half came in with LDL under 100, the level called optimal
❌ 1.4% had the profile the guidelines call ideal
❌ 8 of 9 on the 2004 panel had ties to cholesterol-drug makers (NHLBI)
❌ 10.4 million of the newly eligible Americans with no cardiovascular disease
❌ Heart disease: still the #1 cause of death in America (CDC)
Where a heart attack actually happens
Cholesterol is a number in your blood. A heart attack does not happen in a number. It happens in a blood vessel.
Most heart attacks begin in the artery wall. Plaque builds inside the wall, the surface over it breaks, and a clot forms at the break and closes the artery. (Libby, NEJM, 2013)
So two places decide it. The wall: whether the lining of the vessel is healthy, and whether it can open up when your heart asks for more blood. And the clot: what forms inside the vessel, and whether your body clears it.
Your yearly checkup measures neither. It measures what is circulating. It does not look at how your vessels behave, and it does not look at what is building inside them.
The paid loop
-
A number a pill can lower gets a guideline. Cholesterol has had a federal panel writing its targets for decades.
-
The guideline gets written by experts with ties. In 2004, eight of the nine had financial ties to the companies whose drugs bring that number down.
-
The target drops. 100 became 70 for the highest-risk patients.
-
Eligibility grows. 12.8 million more Americans eligible.
-
What no pill is sold to measure never gets a test. Your vessel wall and the clots inside it are not on your checkup.
-
End of the line. Your results come back normal. So did almost half of theirs.
If your results have always come back normal, that is not your failure. You did what you were told. You watched the number they gave you.
Your father went to bed healthy
Your father is 65. Every year he gets his blood drawn. His LDL comes back under 100, and the doctor uses the same word the guidelines use: optimal.
He goes home believing his heart is fine. Almost half of those 136,905 hospital stays came in with that same number.
Nobody looked at how his vessel walls behave. Nobody looked at what is forming inside them. Those are the two places where a heart attack is decided, and neither one is on his checkup.
What the research found
I spent this year going through the research on those two places, not on the number. What I found surprised me.
Researchers found two things, decades apart and on two continents, that work on exactly those two places: one on the vessel wall, one on what forms inside it.
- Neither can be patented.
- Neither has a panel writing its target.
- One of them is probably already in your kitchen.
In my next email, I’ll show you the first one.
Black Forest exists for one reason: to help Americans live better and break free from a system that profits from their sickness. A system that earns more from a lower line than from a healthier vessel is that system.
We have been working on something built on this research. I believe it is the most revolutionary thing we have made. It is not ready to show you today. When it is, the people on our list hear first.
Don’t miss what we’re building. Join the list.
You hear first when it is ready, and you get the rest of this research as we publish it.
Their number said optimal
136,905 hospital stays. Almost half under the line they were told meant safe.
The line was moved lower by a panel whose members had ties to the companies that sell the pill, and moved again in 2013. The two places where a heart attack is decided were never on the checkup at all.
What did your last checkup say? Tell me in the comments. I read every one.
To your health,
Antonio
CEO, Black Forest Supplements
